Patents by Inventor Matthew Paul Baker
Matthew Paul Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10059750Abstract: The present application relates to compositions of modified toxins exhibiting cytotoxicity and/or reduced immunogenicity. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. A modified diphtheria toxin or fusion protein may be administered with one or more other agents.Type: GrantFiled: March 11, 2014Date of Patent: August 28, 2018Assignee: ANGELICA THERAPEUTICS, INC.Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
-
Publication number: 20170210820Abstract: The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.Type: ApplicationFiled: March 28, 2017Publication date: July 27, 2017Inventors: Timothy David Jones, Matthew Paul Baker
-
Patent number: 9339781Abstract: The present invention relates to a method of preparing an aqueous dispersion of polymer encapsulated particulate material, the method comprising: providing a dispersion of the particulate material in a continuous aqueous phase, the dispersion comprising ethylenically unsaturated monomer and a stabilizer for the particulate material; and polymerizing the ethylenically unsaturated monomer by non-living free radical polymerization to form polymer that encapsulates the particulate material, thereby providing the aqueous dispersion of polymer encapsulated particulate material; wherein polymerization of the ethylenically unsaturated monomer comprises: (a) polymerizing a monomer composition that includes ionizable ethylenically unsaturated monomer so as to form a base responsive water swellable non-living polymer layer that encapsulates the particulate material; and (b) polymerizing a monomer composition that includes non-ionizable ethylenically unsaturated monomer so as to form an extensible, water and base permeabType: GrantFiled: May 31, 2012Date of Patent: May 17, 2016Assignee: The University of SydneyInventors: Matthew Paul Baker, Timothy Warren Davey, Brian Stanley Hawkett, Duc Ngoc Nguyen, Christopher Henry Such
-
Publication number: 20160009768Abstract: The present application relates to compositions of modified toxins exhibiting cytotoxicity and/or reduced immunogenicity. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. A modified diphtheria toxin or fusion protein may be administered with one or more other agents.Type: ApplicationFiled: March 11, 2014Publication date: January 14, 2016Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Jane Alyson Rust, Simon Keen
-
Publication number: 20150031860Abstract: The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.Type: ApplicationFiled: July 7, 2014Publication date: January 29, 2015Inventors: Timothy David Jones, Matthew Paul Baker
-
Publication number: 20150031550Abstract: The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.Type: ApplicationFiled: July 7, 2014Publication date: January 29, 2015Inventors: Timothy David Jones, Matthew Paul Baker
-
Publication number: 20140329932Abstract: The present invention relates to a method of preparing an aqueous dispersion of polymer encapsulated particulate material, the method comprising: providing a dispersion of the particulate material in a continuous aqueous phase, the dispersion comprising ethylenically unsaturated monomer and a stabiliser for the particulate material; and polymerising the ethylenically unsaturated monomer by non-living free radical polymerisation to form polymer that encapsulates the particulate material, thereby providing the aqueous dispersion of polymer encapsulated particulate material; wherein polymerisation of the ethylenically unsaturated monomer comprises: (a) polymerising a monomer composition that includes ionisable ethylenically unsaturated monomer so as to form a base responsive water swellable non-living polymer layer that encapsulates the particulate material; and (b) polymerising a monomer composition that includes non-ionisable ethylenically unsaturated monomer so as to form an extensible, water and base permeabType: ApplicationFiled: May 31, 2012Publication date: November 6, 2014Applicant: THE UNIVERSITY OF SYDNEYInventors: Matthew Paul Baker, Timothy Warren Davey, Brian Stanley Hawkett, Duc Ngoc Nguyen, Christopher Henry Such
-
Publication number: 20140005361Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.Type: ApplicationFiled: August 26, 2013Publication date: January 2, 2014Applicant: MERCK PATENT GMBHInventors: Stephen D. Gillies, Nigel John Watkins, Matthew Paul Baker, Kin-Ming Lo, Steven C. Degon
-
Patent number: 8557232Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.Type: GrantFiled: February 27, 2009Date of Patent: October 15, 2013Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Nigel John Watkins, Matthew Paul Baker, Kin-Ming Lo, Steven C. Degon
-
Patent number: 8470314Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.Type: GrantFiled: December 15, 2008Date of Patent: June 25, 2013Assignee: Angelica Therapeutics, Inc.Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
-
Publication number: 20120289417Abstract: The invention relates to databases of T cell epitopes, especially helper T cell epitopes, for rapid interrogation of protein sequences for the presence of T cell epitopes. The invention includes full or partial databases and data structures of T cell epitopes including epitopes identified especially by ex vivo T cell assays with test peptides and includes T cell epitopes identified by extrapolation of data from test peptides. The present invention also includes high throughput methods for determining the T cell epitope activity of peptides for subsequent inclusion in databases and data structures including methods where subsets of T cell especially regulatory T cells are removed or inhibited from T cell assays in order to maximize the sensitivity of detection of T cell epitope activity.Type: ApplicationFiled: July 31, 2012Publication date: November 15, 2012Applicant: ANTITOPE LIMITEDInventors: Frank Carr, Matthew Paul Baker
-
Patent number: 8252897Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.Type: GrantFiled: June 20, 2008Date of Patent: August 28, 2012Assignee: Angelica Therapeutics, Inc.Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
-
Patent number: 7670595Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.Type: GrantFiled: June 27, 2005Date of Patent: March 2, 2010Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Nigel John Watkins, Matthew Paul Baker, Kin-Ming Lo
-
Publication number: 20100017370Abstract: The invention relates to databases of T cell epitopes, especially helper T cell epitopes, for rapid interrogation of protein sequences for the presence of T cell epitopes. The invention includes full or partial databases and data structures of T cell epitopes including epitopes identified especially by ex vivo T cell assays with test peptides and includes T cell epitopes identified by extrapolation of data from test peptides. The present invention also includes high throughput methods for determining the T cell epitope activity of peptides for subsequent inclusion in databases and data structures including methods where subsets of T cell especially regulatory T cells are removed or inhibited from T cell assays in order to maximize the sensitivity of detection of T cell epitope activity.Type: ApplicationFiled: October 11, 2007Publication date: January 21, 2010Applicant: ANTITOPE LIMITEDInventors: Francis Joseph Carr, Matthew Paul Baker
-
Publication number: 20090221500Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.Type: ApplicationFiled: December 15, 2008Publication date: September 3, 2009Applicant: Angelica Therapeutics, Inc.Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
-
Publication number: 20090191154Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.Type: ApplicationFiled: February 27, 2009Publication date: July 30, 2009Applicant: Merck Patent GmbHInventors: Stephen D. Gillies, Nigel John Watkins, Matthew Paul Baker, Kin-Ming Lo, Steven C. Degon
-
Publication number: 20090041797Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.Type: ApplicationFiled: June 20, 2008Publication date: February 12, 2009Applicant: ANGELICA THERAPEUTICS, INC.Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
-
Publication number: 20080206239Abstract: The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.Type: ApplicationFiled: February 3, 2006Publication date: August 28, 2008Applicant: ANTITOPE LIMITEDInventors: Timothy David Jones, Matthew Paul Baker